| Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy C Girmenia, GM Rossolini, A Piciocchi, A Bertaina, G Pisapia, D Pastore, ... Bone marrow transplantation 50 (2), 282-288, 2015 | 190 | 2015 |
| Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection L Arcaini, C Besson, M Frigeni, H Fontaine, M Goldaniga, M Casato, ... Blood, The Journal of the American Society of Hematology 128 (21), 2527-2532, 2016 | 188 | 2016 |
| Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab A Rambaldi, G Gritti, MC Micò, M Frigeni, G Borleri, A Salvi, F Landi, ... Immunobiology 225 (6), 152001, 2020 | 149 | 2020 |
| Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support G Gritti, F Raimondi, D Ripamonti, I Riva, F Landi, L Alborghetti, M Frigeni, ... | 130 | 2020 |
| IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study G Gritti, F Raimondi, D Ripamonti, I Riva, F Landi, L Alborghetti, M Frigeni, ... Medrxiv, 2020.04. 01.20048561, 2020 | 94 | 2020 |
| Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study S Luminari, M Merli, S Rattotti, V Tarantino, L Marcheselli, F Cavallo, ... Blood, The Journal of the American Society of Hematology 134 (10), 798-801, 2019 | 83 | 2019 |
| Direct‐acting antivirals in hepatitis C virus‐associated diffuse large B‐cell lymphomas M Merli, M Frigeni, L Alric, C Visco, C Besson, L Mannelli, A Di Rocco, ... The Oncologist 24 (8), e720-e729, 2019 | 64 | 2019 |
| Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 G Gritti, F Raimondi, B Bottazzi, D Ripamonti, I Riva, F Landi, L Alborghetti, ... Leukemia 35 (9), 2710-2714, 2021 | 59 | 2021 |
| Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection M Frigeni, C Besson, C Visco, H Fontaine, M Goldaniga, M Visentini, ... Leukemia 34 (5), 1462-1466, 2020 | 41 | 2020 |
| Independent prognostic impact of tumour‐infiltrating macrophages in early‐stage Hodgkin's lymphoma M Gotti, M Nicola, M Lucioni, V Fiaccadori, V Ferretti, R Sciarra, ... Hematological Oncology 35 (3), 296-302, 2017 | 31 | 2017 |
| Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network S Rattotti, VV Ferretti, C Rusconi, A Rossi, S Fogazzi, L Baldini, P Pioltelli, ... Hematological Oncology 37 (2), 160-167, 2019 | 21 | 2019 |
| Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma M Merli, I Defrancesco, C Visco, C Besson, A Di Rocco, A Arcari, A Sica, ... Leukemia & Lymphoma 61 (9), 2122-2128, 2020 | 20 | 2020 |
| Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort C Gurnari, MR Pascale, A Vitale, E Diral, A Tomelleri, E Galossi, G Falconi, ... American Journal of Hematology 99 (2), 254-262, 2024 | 17 | 2024 |
| Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis M Lemaitre, P Brice, M Frigeni, O Hermine, L Arcaini, C Thieblemont, ... Journal of Infection 80 (2), 219-224, 2020 | 16 | 2020 |
| Direct‐acting antivirals during or after immunochemotherapy in hepatitis C virus–positive diffuse large B‐cell lymphomas M Merli, M Frigeni, M Gotti, P Grossi, R Bruno, F Passamonti, L Arcaini Hepatology 66 (4), 1341-1343, 2017 | 12 | 2017 |
| Targeted next‐generation sequencing reveals molecular heterogeneity in non‐chronic lymphocytic leukemia clonal B‐cell lymphocytosis I Defrancesco, S Zibellini, E Boveri, M Frigeni, VV Ferretti, E Rizzo, ... Hematological Oncology 38 (5), 689-697, 2020 | 11 | 2020 |
| Mutational and immunogenetic landscape of HCV‐associated B‐cell lymphoproliferative disorders I Defrancesco, M Visentini, S Zibellini, YA Minafò, S Rattotti, VV Ferretti, ... American Journal of Hematology 96 (6), E210, 2021 | 10 | 2021 |
| Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination D Taurino, M Frigeni, A Grassi, G Cavallaro, S Salmoiraghi, O Spinelli, ... Mediterranean Journal of Hematology and Infectious Diseases 13 (1), 2021 | 10 | 2021 |
| Dose escalation of HLA-A2-WT1 CD3 T-cell bispecific antibody in a phase I study in patients with relapsed/refractory acute myeloid leukemia (AML) M Hutchings, P Montesinos, A Santoro, HA Hou, MP Martinez-Sanchez, ... Blood 142, 1537, 2023 | 7 | 2023 |
| Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts L Lanino, F Restuccia, A Perego, M Ubezio, B Fattizzo, M Riva, ... American Journal of Hematology 98 (8), E204-E208, 2023 | 7 | 2023 |
